WCN26-4220 CLINICAL OUTCOMES AFTER ERYTHROPOIESIS-STIMULATING AGENT THERAPY IN HEMODIALYSIS PATIENTS AMONG THAILAND REIMBURSEMENTS

Read full text Summarise with VIRAT
Authors: Supoj Chueachinda, Pichaya Tantiyavarong
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Anemia is prevalent among hemodialysis (HD) patients and is associated with cardiovascular events and mortality. Erythropoiesis-stimulating agents (ESA) are essential for management; however, access varies across healthcare schemes, and regulatory constraints may impede achieving target hemoglobin (Hb) levels. This study aimed to compare clinical outcomes across different ESA reimbursement policies in Thailand.

Fields of Study & Subjects

Erythropoietin and Anemia Treatment Dialysis and Renal Disease Management Biosimilars and Bioanalytical Methods

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104221–104221
Publication date
25 March 2026
Language
EN